Home › Funds › Enavate Sciences GP, LLC › ZBIO
Enavate Sciences GP, LLC position in ZBIO
ZENAS BIOPHARMA INC COM · Health Care
Enavate Sciences GP, LLC reported holding 3,919,159 shares of ZBIO (ZENAS BIOPHARMA INC COM) in its Q2 2026 13F filing — a position valued at US$99.5M, representing 28.80% of its reported portfolio and ranking #2 among its reported holdings. Enavate Sciences GP, LLC has disclosed ZBIO holdings in 7 of the last 7 reported quarters, going back to Q4 2024.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Enavate Sciences GP, LLC's ZBIO position evolved
Enavate Sciences GP, LLC first disclosed a stake in ZBIO in Q4 2024 at 3,761,359 shares (US$30.8M). The position peaked in Q4 2025 at 3,919,159 shares, worth US$142.3M. Across 7 filings, Enavate Sciences GP, LLC increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 5 time(s). The most recent filing (Q2 2026) shows 3,919,159 shares valued at US$99.5M.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2024 | 3.76M | $30.81M | New |
| Q1 2025 | 3.76M | $29.71M | Hold |
| Q2 2025 | 3.76M | $36.45M | Hold |
| Q3 2025 | 3.76M | $83.50M | Hold |
| Q4 2025 | 3.92M | $142.30M | Add |
| Q1 2026 | 3.92M | $76.62M | Hold |
| Q2 2026 | 3.92M | $99.47M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About ZBIO and 13F data
ZBIO (ZENAS BIOPHARMA INC COM) is a Health Care company. 68 other funds we track also report a position in ZBIO — the largest reported positions include SR ONE CAPITAL MANAGEMENT, LP (US$127.9M), NEA Management Company, LLC (US$102.1M), DEERFIELD MANAGEMENT COMPANY, L.P. (US$80.3M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding ZBIO
- SR ONE CAPITAL MANAGEMENT, LP 5.04M sh · $127.86M · Q2 2026
- NEA Management Company, LLC 4.02M sh · $102.11M · Q2 2026
- DEERFIELD MANAGEMENT COMPANY, L.P. 67.20M sh · $80.32M · Q2 2026
- Royalty Pharma Sub-Manager, LLC 2.39M sh · $60.61M · Q2 2026
- Fairmount Funds Management LLC 2.36M sh · $59.87M · Q2 2026
- NVP Associates, LLC 1.84M sh · $46.66M · Q2 2026
- Context Capital Management, LLC 35.80M sh · $42.60M · Q2 2026
- EcoR1 Capital, LLC 789.50K sh · $20.04M · Q2 2026
- ArrowMark Colorado Holdings LLC 573.32K sh · $14.55M · Q2 2026
- SILVERARC CAPITAL MANAGEMENT, LLC 509.79K sh · $12.94M · Q2 2026
- Rock Springs Capital Management LP 502.08K sh · $12.74M · Q2 2026
- Pivotal bioVenture Partners Investment Advisor LLC 490.77K sh · $12.46M · Q2 2026
More on Enavate Sciences GP, LLC
FAQ
How long has Enavate Sciences GP, LLC held ZBIO?
Enavate Sciences GP, LLC has disclosed ZBIO holdings in 7 of the last 7 reported quarters, going back to Q4 2024.
What is Enavate Sciences GP, LLC's current position in ZBIO?
As of Q2 2026, Enavate Sciences GP, LLC holds 3.92M shares of ZBIO (ZENAS BIOPHARMA INC COM), valued at $99.47M, representing 28.80% of its reported portfolio and ranking #2.
Has Enavate Sciences GP, LLC been buying or selling ZBIO?
In the latest 13F filing (Q2 2026), Enavate Sciences GP, LLC held unchanged its position in ZBIO. The position peaked in Q4 2025 at 3.92M shares.
Which other funds hold ZBIO?
Other major institutional holders of ZBIO include SR ONE CAPITAL MANAGEMENT, LP, NEA Management Company, LLC, DEERFIELD MANAGEMENT COMPANY, L.P., among 68 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.